Remdesivir is the only drug found so far to potentially shorten recovery time from COVID-19. On May 1, the U.S. Food and Drug Administration authorized emergency use of this antiviral medication for patients with severe disease. The Minnesota Department of Health has worked with the Minnesota COVID Ethics Collaborative (MCEC) to create an ethical framework for distributing the state’s allocation of the drug. MCEC is co-led by Profs. Debra DeBruin and Susan M. Wolf. DeBruin is Interim Director of the Center for Bioethics, a Consortium member center, and Wolf is Chair of the Consortium. Read the “Ethical Framework for May 2020 Allocation of Remdesivir in the COVID-19 Pandemic” here. More information about the challenges of allocating remdesiver is available here.
Tuesday, May 19, 2020